Cited by 11,486Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, Thomas J., Bell, Daphne W., Sordella, Raffaella, Gurubhagavatula, Sarada, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Haserlat, Sara M., Supko, Jeffrey G., Haluska, Frank G., Louis, David N., Christiani, David C., Settleman, Jeff, Haber, Daniel A.·2004·New England Journal of Medicine

DOI 10.1056/nejmoa040938

Open this paper in CoChat — free account

Abstract

BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown. METHODS: We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib. The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells. RESULTS: Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001). Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain. Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8 percent). All mutations were heterozygous, and identical mutations were observed in multiple patients, suggesting an additive specific gain of function. In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib. CONCLUSIONS: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.

Integrity signals

Registry

Crossref · 10.1056/nejmoa040938

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., den Abbeele, A. D. V., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,306
Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr/abl Gene of the Philadelphia Chromosome
Daley, G. Q., Etten, R. A. V., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 2,141

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 3

Wakeling AE, 2002, Cancer Res, 62, 5749
Frederick L, 2000, Cancer Res, 60, 1383
Li B, 2003, Cancer Res, 63, 7443

Sorted by citations

Items 701–800 of 1,081

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
Prostaglandin E2 Activates Mitogen-Activated Protein Kinase/Erk Pathway Signaling and Cell Proliferation in Non–Small Cell Lung Cancer Cells in an Epidermal Growth Factor Receptor–Independent Manner
Krysan, K., Reckamp, K. L., Dalwadi, H. N., Sharma, S. P., Rozengurt, E., Dohadwala, M., & Dubinett, S. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0216 · Cited by 231
Ligand‐dependent responses of the ErbB signaling network: experimental and modeling analyses
Birtwistle, M. R., Okada, M., Yumoto, N., Ogunnaike, B. A., Hoek, J. B., & Kholodenko, B. Ν. (2007) · Molecular Systems Biology · doi:10.1038/msb4100188 · Cited by 231
Precision Medicine from a Public Health Perspective
Ramaswami, R., Bayer, R., & Galea, S. (2017) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040617-014158 · Cited by 243
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
Ye, X., Li, Y., Stawicki, S. S., Couto, S. S., Eastham‐Anderson, J., Kallop, D. Y., Weimer, R. M., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 231
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-75 · Cited by 234
Non‐solid oncogenes in solid tumors: EML4–ALK fusion genes in lung cancer
Mano, H. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00972.x · Cited by 232
Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways
Shukla, N. N., Ameur, N., Yılmaz, İ., Nafa, K., Lau, C.-Y., Marchetti, A., Borsu, L. A., Barr, F. G., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2056 · Cited by 235
First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study
Park, K., Yu, C.-J., Kim, S.-W., Lin, M.-C., Sriuranpong, V., Tsai, C.-M., Lee, J.-S., Kang, J.-H., Chan, K. C. A., Perez-Moreno, P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4921 · Cited by 229
Clinical next‐generation sequencing in patients with non–small cell lung cancer
Hagemann, I. S., Devarakonda, S. H. K., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., et al. (2014) · Cancer · doi:10.1002/cncr.29089 · Cited by 232
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation
Luppi, F., Longo, A. M., de Boer, W. I., Rabe, K. F., & Hiemstra, P. S. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.11.014 · Cited by 229
Mechanisms of Disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer
Tao, Y., Pinzi, V., Bourhis, J., & Deutsch, É. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0934 · Cited by 234
Human malignant melanoma: detection of BRAF- and c-kit–activating mutations by high-resolution amplicon melting analysis
Willmore‐Payne, C., Holden, J. A., Tripp, S. R., & Layfield, L. J. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.03.015 · Cited by 227
Pharmacogenetics and Pharmacogenomics: Development, Science, and Translation
Weinshilboum, R. M., & Wang, L. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162315 · Cited by 235
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
Cortés-Funes, H., Gómez, C. G., Rosell, R., Valero, P. M., Girón, C. G., Velasco, A., Izquierdo, Á., Díz, P., Camps, C., Castellanos, D., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi221 · Cited by 229
Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., Park, K., Nam, S. W., Park, W. S., Kim, S. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0976 · Cited by 228
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 234
The impact of systems approaches on biological problems in drug discovery
Hood, L., & Perlmutter, R. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1004-1215 · Cited by 227
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 241
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
Omuro, A. M. P., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N. T., Milton, D. T., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21033 · Cited by 227
KRAS Mutation: Should We Test for It, and Does It Matter?
Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 233
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group
Thunnissen, E., Kerr, K. M., Herth, F. J. F., Lantuéjoul, S., Papotti, M. G., Rintoul, R. C., Rossi, G., Skov, B. G., Weynand, B., Bubendorf, L., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.10.017 · Cited by 228
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Soh, J., Okumura, N., Lockwood, W. W., Yamamoto, H., Shigematsu, H., Zhang, W., Chari, R., Shames, D. S., Tang, X., MacAulay, C. E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007464 · Cited by 227
Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway
Hassan, B., Akçakanat, A., Holder, A. M., & Meric‐Bernstam, F. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.008 · Cited by 230
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913c9f · Cited by 233
Tyrphostins and Other Tyrosine Kinase Inhibitors
Levitzki, A., & Mishani, E. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142657 · Cited by 225
Rare Pulmonary Neuroendocrine Cells Are Stem Cells Regulated by Rb, p53, and Notch
Ouadah, Y., Rojas, E., Riordan, D. P., Capostagno, S., Kuo, C. S., & Krasnow, M. A. (2019) · Cell · doi:10.1016/j.cell.2019.09.010 · Cited by 223
Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECIST
Ratain, M. J., & Eckhardt, S. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.960 · Cited by 227
EGFR and KRAS mutations in lung carcinoma
Billah, S., Stewart, J., Staerkel, G., Chen, S., Gong, Y., & Guo, M. (2011) · Cancer Cytopathology · doi:10.1002/cncy.20151 · Cited by 226
Comprehensive assessment of cancer missense mutation clustering in protein structures
Kamburov, A., Lawrence, M. S., Polak, P. P., Leshchiner, I., Lage, K., Golub, T. R., Lander, E. S., & Getz, G. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516373112 · Cited by 222
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Natale, R. B., Bodkin, D., Govindan, R., Sleckman, B. G., Rizvi, N. A., Capó, A., Germonpré, P. R., Eberhardt, W., Stockman, P. K., Kennedy, S. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6015 · Cited by 226
Pharmacogenetics/genomics and personalized medicine
Sadée, W., & Dai, Z. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi261 · Cited by 227
Erlotinib hydrochloride
Dowell, J. E., Minna, J. D., & Kirkpatrick, P. N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1612 · Cited by 222
Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)
Elkind, N. B., Szentpétery, Z., Apáti, Á., Özvegy‐Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 223
Mechanisms of Acquired Resistance to AZD9291
Kim, T. M., Song, A., Kim, D., Kim, S., Ahn, Y., Keam, B., Jeon, Y. K., Lee, S., Chung, D. H., & Heo, D. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000688 · Cited by 225
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Gonzales, A. J., Hook, K. E., Althaus, I. W., Ellis, P. A., Trachet, E., Delaney, A. M., Harvey, P. J., Ellis, T. A., Amato, D. M., Nelson, J. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2232 · Cited by 226
Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
Marek, L. A., Ware, K. E., Fritzsche, A., Hercule, P., Helton, W. R., Smith, J. E., McDermott, L. A., Coldren, C. D., Nemenoff, R. A., Merrick, D. T., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049544 · Cited by 225
The cellular origin for malignant glioma and prospects for clinical advancements
Zong, H., Verhaak, R. G. W., & Canoll, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.30 · Cited by 234
Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor SurvivalIn vivoin Non–Small Cell Lung Cancer
Haura, E. B., Zheng, Z., Song, L., Cantor, A. B., & Bepler, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0827 · Cited by 227
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
Gion, P. D., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224
Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
Suda, K., Tomizawa, K., & Mitsudomi, T. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9209-4 · Cited by 226
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology
Ou, S. I., Bartlett, C. H., Mino-Kenudson, M. A., Cui, J., & Iafrate, A. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0311 · Cited by 226
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
Eck, M. J., & Yun, C.-H. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.010 · Cited by 225
Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study
Garland, L. L., Rankin, C. J., Gandara, D. R., Rivkin, S. E., Scott, K., Nagle, R. B., Klein–Szanto, A. J., Testa, J. R., Altomare, D. A., & Borden, E. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7634 · Cited by 220
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0887-2 · Cited by 216
EGFR and NF-κB: partners in cancer
Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 222
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
Janmaat, M. L., Gallegos-Ruiz, M. I., Rodríguez, J. A., Meijer, G. A., Vervenne, W. L., Richel, D. J., van Groeningen, C. J., & Giaccone, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4900 · Cited by 218
Recent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 222
Lung cancer epigenetics and genetics
Risch, A., & Plass, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23605 · Cited by 227
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823ab0dd · Cited by 226
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line
Rho, J. K., Choi, Y. J., Lee, J. K., Ryoo, B., Na, I. I., Yang, S. H., Kim, C. H., & Lee, J. C. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.017 · Cited by 220
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3106 · Cited by 220
Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR
Watanabe, M., Kawaguchi, T., Isa, S.-I., Ando, M., Tamiya, A., Kubo, A., Saka, H., Takeo, S., Adachi, H., Tagawa, T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2151 · Cited by 216
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 226
Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen
Johnson, J. R., Cohen, M. H., Sridhara, R., Chen, Y., Williams, G. M., Duan, J. Z., Gobburu, J. V. S., Booth, B. P., Benson, K. A., Leighton, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0790 · Cited by 224
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Kelloff, G. J., Krohn, K. A., Larson, S. M., Weissleder, R., Mankoff, D. A., Hoffman, J. M., Link, J. M., Guyton, K. Z., Eckelman, W. C., Scher, H. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1302 · Cited by 223
DNA-microarray analysis of brain cancer: molecular classification for therapy
Mischel, P. S., Cloughesy, T. F., & Nelson, S. F. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1518 · Cited by 220
The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review
Hirsch, F. R., Spreafico, A., Novello, S., Wood, M. D., Simms, L., & Papotti, M. G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f551 · Cited by 219
EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
Takano, T., Fukui, T., Ohe, Y., Tsuta, K., Yamamoto, S., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Furuta, K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7254 · Cited by 220
Estrogen receptor signaling pathways in human non-small cell lung cancer
Márquez‐Garbán, D. C., Chen, H., Fishbein, M. C., Goodglick, L., & Pietras, R. J. (2007) · Steroids · doi:10.1016/j.steroids.2006.11.019 · Cited by 218
Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
Héon, S., Yeap, B. Y., Britt, G. J., Costa, D. B., Rabin, M. S., Jackman, D. M., & Johnson, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1588 · Cited by 217
Non–Small Cell Lung Cancers with Kinase Domain Mutations in the Epidermal Growth Factor Receptor Are Sensitive to Ionizing Radiation
Das, A. K., Sato, M., Story, M. D., Peyton, M., Graves, R., Redpath, S., Girard, L., Gazdar, A. F., Shay, J. W., Minna, J. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2627 · Cited by 217
Biological and clinical implications of EGFR mutations in lung cancer
Mitsudomi, T., Kosaka, T., & Yatabe, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0583-4 · Cited by 218
Posttranslational Protein Modifications
Krueger, K. E., & Srivastava, S. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r600009-mcp200 · Cited by 217
The estimation of tumor cell percentage for molecular testing by pathologists is not accurate
Smits, A. J. J., Kummer, J. A., de Bruin, P. C., Bol, M., van den Tweel, J. G., Seldenrijk, K. A., Willems, S. M., Offerhaus, G. J. A., de Weger, R. A., van Diest, P. J., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.134 · Cited by 213
Cancer pharmacogenomics: strategies and challenges
Wheeler, H. E., Maitland, M. L., Dolan, M. E., Cox, N. J., & Ratain, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3352 · Cited by 221
Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study
Crinò, L., Cappuzzo, F., Zatloukal, P., Reck, M., Pešek, M., Thompson, J., Ford, H. E. R., Hirsch, F. R., Varella‐Garcia, M., Ghiorghiu, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0672 · Cited by 214
Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
Liu, X., Wang, P., Zhang, C., & Ma, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.16854 · Cited by 222
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes
Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010) · Cancer · doi:10.1002/cncr.24816 · Cited by 217
Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method
Pao, W. J., & Ladanyi, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1387 · Cited by 214
The Evolving War on Cancer
Haber, D. A., Gray, N. S., & Baselga, J. M. (2011) · Cell · doi:10.1016/j.cell.2011.03.026 · Cited by 219
Self-citation
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery
THOMPSON, N., & LYONS, J. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.04.007 · Cited by 217
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening
Jänne, P. A., Borras, A. M., Kuang, Y., Rogers, A. M., Joshi, V. A., Liyanage, H., Lindeman, N., Lee, J. C., Halmos, B., Maher, E. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2047 · Cited by 214
Biology of Interactions: Antiepidermal Growth Factor Receptor Agents
Harari, P. M., Allen, G. W., & Bonner, J. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8984 · Cited by 214
EGFR Mutations in Lung Adenocarcinomas
Li, A. R., Chitale, D. A., Riely, G. J., Pao, W. J., Miller, V. A., Zakowski, M. F., Rusch, V. W., Kris, M. G., & Ladanyi, M. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070178 · Cited by 214
Membrane‐anchored growth factors, the epidermal growth factor family: Beyond receptor ligands
Higashiyama, S., Iwabuki, H., Morimoto, C., Hieda, M., Inoue, H., & Matsushita, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00676.x · Cited by 213
Molecular predictive and prognostic markers in non-small-cell lung cancer
Coate, L. E., John, T., Tsao, M., & Shepherd, F. A. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70155-x · Cited by 214
Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer
Puri, N., & Salgia, R. (2008) · Journal of Carcinogenesis · doi:10.4103/1477-3163.44372 · Cited by 210
Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features
Finberg, K. E., Sequist, L. V. D., Joshi, V. A., Muzikansky, A., Miller, J. M., Han, M., Beheshti, J., Chirieac, L. R., Mark, E. J., & Iafrate, A. J. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060182 · Cited by 212
Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
Kobayashi, S., Canepa, H. M., Bailey, A. S., Nakayama, S., Yamaguchi, N., Goldstein, M. A., Huberman, M. S., & Costa, D. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182781e35 · Cited by 213
High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization
Naylor, T. L., Greshock, J. D., Wang, Y., Colligon, T. A., Yu, Q., Clemmer, V. B., Zaks, T. Z., & Weber, B. L. (2005) · Breast Cancer Research · doi:10.1186/bcr1356 · Cited by 214
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial
Cappuzzo, F., Ligorio, C., Janne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Tisch, A. H., Magrini, E., Finocchiaro, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4300 · Cited by 210
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer
Gow, C., Chang, Y., Hsu, Y.-C., Tsai, M.-F., Wu, C., Yu, C., Yang, J. C., Lee, Y., Yang, P., & Shih, J. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn679 · Cited by 213
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer
Tulchinsky, E. M., Demidov, O. N., Kriajevska, M. V., Barlev, N. A., & Имянитов, Е. Н. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.10.003 · Cited by 214
Precision medicine in non-small cell lung cancer: Current applications and future directions
Yang, S., Schultheis, A. M., Yu, H. A., Mandelker, D. L., Ladanyi, M., & Büttner, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.009 · Cited by 220
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 214
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Motzer, R. J., Bukowski, R. M., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Kim, S. T., Baum, C. M., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23776 · Cited by 211
Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway
Schnidar, H., Eberl, M., Klingler, S., Mangelberger, D., Kasper, M., Hauser‐Kronberger, C., Regl, G., Kroismayr, R., Moriggl, R., Sibilia, M. C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2331 · Cited by 212
Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas
Ceppa, D. P., Kris, M. G., Riely, G. J., Sarkaria, I. S., McDonough, T. L., Chuai, S., Venkatraman, E. S., Miller, V. A., Ladanyi, M., Pao, W. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3224 · Cited by 210
Osimertinib-Induced Cardiotoxicity
Anand, K., Ensor, J., Trachtenberg, B. H., & Bernicker, E. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.10.006 · Cited by 217
Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio, K., Itoh, Y., Jiang, H., Duffield, E. L., McCormack, R., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307f98 · Cited by 209
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Franceschi, E., Cavallo, G., Lonardi, S., Magrini, E., Tosoni, A., Grosso, D., Scopece, L., Blatt, V., Urbini, B., Pession, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603669 · Cited by 211
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers
Ebi, H., Corcoran, R. B., Singh, A., Chen, Z., Song, Y., Lifshits, E., Ryan, D. P., Meyerhardt, J. A., Benes, C., Settleman, J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57909 · Cited by 210
Self-citation
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Camp, E. R., Summy, J. M., Bauer, T. W., Liu, W., Gallick, G. E., & Ellis, L. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.397.11.1 · Cited by 210
Genetics of Biliary Tract Cancers and Emerging Targeted Therapies
Hezel, A. F., Deshpande, V., & Zhu, A. X. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4787 · Cited by 212
Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer
Janssen-Heijnen, M. L. G. (2004) · Thorax · doi:10.1136/thx.2003.018044 · Cited by 210
High-throughput phenotyping of lung cancer somatic mutations
Berger, A. H., Brooks, A. N., Wu, X., Shrestha, Y., Chouinard, C., Piccioni, F., Bagul, M., Kamburov, A., Imielinski, M., Hogstrom, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.022 · Cited by 192
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210

Authors: Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., & Haber, D. A.
Affiliations: Harvard University (US)
ORCID: Lynch, Thomas J.
Bell, Daphne W.
Sordella, Raffaella
Okimoto, Ross A.
Supko, Jeffrey G.
Louis, David N.
Christiani, David C.
Haber, Daniel A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2004-05-20
Volume: 350
Issue: 21
Pages: 2129-2139
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa040938
OpenAlex: W2043696829
Cited by: 11,486
References: 31
Citations by year: 2026: 194 · 2025: 220 · 2024: 236 · 2023: 380 · 2022: 328 · 2021: 374 · 2020: 421 · 2019: 388 · 2018: 490 · 2017: 561 · 2016: 616 · 2015: 673 · 2014: 679 · 2013: 691 · 2012: 683
FWCI: 606.47
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Funders: U.S. Public Health Service (P01 95281)
National Cancer Institute (P30-CA0516, R01CA092824, P50CA090578)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: non-small cell lung cancer, epidermal growth factor receptor, gefitinib, EGFR mutation, tyrosine kinase inhibitors, drug sensitivity, ATP binding site, gain-of-function mutations, tyrosine kinase activity, predictive biomarkers, targeted therapy
MeSH terms: Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Epidermal Growth Factor, Female, Heterozygote, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Protein-Tyrosine Kinases, Quinazolines, Sequence Deletion, Genes, erbB-1, Drug Resistance, Neoplasm, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks